Overview
Dr. Visvanathan is a Professor on faculty at Johns Hopkins. She is a practicing medical oncologist and cancer epidemiologist focused on translating discoveries to the clinic and population as a whole. She directs the Clinical Cancer Genetics and Prevention service at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (SKCCC) and is an active member of the Breast and Ovarian Program and Cancer Prevention and Control Program. Dr. Visvanathan is also Director of the Cancer Epidemiology Track in the Department of Epidemiology at Johns Hopkins Bloomberg School of Public Health. With her research centered on primary and secondary prevention of breast and ovarian cancer, her goal is to reduce the incidence of and mortality from breast cancer globally by conducting impactful studies at the local, national, and international levels. Specifically, she focuses on the identification of atrisk groups, potential biomarkers of risk and prognosis and evaluation of preventive agents across the continuum. She conducts both observational studies and early phase clinical trials. She also teaches and mentors the next generation of clinicians and cancer researchers. Dr. Visvanathan has also served on national committees focused on Breast Cancer Risk Reduction, Breast Cancer Genetics and Cancer Disparities. She has also co-chaired National Guidelines on Breast Cancer Endocrine Prevention. Locally, serving on the Maryland State Cancer Council. Dr. Visvanathan received her medical degree from the University of Sydney in Australia. She subsequently went on to complete training in internal medicine and medical oncology, including a period as chief resident at Royal Prince Alfred Hospital. She then did further training in Medical Oncology at Johns Hopkins and also obtained a master’s degree in clinical/cancer epidemiology at Johns Hopkins Bloomberg School of Public Health. This was followed by a postdoctoral fellow before coming on to faculty in both the Johns Hopkins School of Medicine and Bloomberg School of Public Health.
Dr. Visvanathan is rated as an Advanced provider by MediFind in Hormone Replacement Therapy (HRT). Her top areas of expertise are Breast Cancer, Ovarian Cancer, Menopause, Hormone Replacement Therapy (HRT), and Salpingo-Oophorectomy.
Her clinical research consists of co-authoring 278 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 5 articles in the study of Hormone Replacement Therapy (HRT).
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- INDEMNITY
- POS
- PPO
Locations
Viragh BLDG 10th FL, Baltimore, MD 21287
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
2 Clinical Trials
Skip Viragh Outpatient Cancer Center
Dr. Samuel Denmeade is the R. Dale Hughes Professor of Oncology and Urology at the Johns Hopkins University School of Medicine and Director of the Genitourinary Oncology Division for the Johns Hopkins Kimmel Cancer Center. He also has appointments in the Department of Pharmacology and Molecular Sciences and Department of Biomolecular Engineering. His areas of clinical expertise include bladder cancer, kidney cancer, prostate cancer and testicular cancer. Dr. Denmeade earned his M.D. from the Columbia College of Physicians and Surgeons of Columbia University. He completed his residency at the University of Chicago. He performed a fellowship in oncology at The Johns Hopkins Hospital and a fellowship in medical oncology at the Johns Hopkins University School of Medicine. His research interests include prostate cancer, bipolar androgen therapy, clinical trials and targeted drug development. Dr. Denmeade has published over 200 papers in the area of prostate cancer research. He has received extensive funding from the NIH, the Department of Defense Prostate Cancer Research Fund and the Prostate Cancer Foundation. He is the Editor-in-Chief of the medical journal The Prostate. Dr. Denmeade is rated as a Distinguished provider by MediFind in Hormone Replacement Therapy (HRT). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Prostatectomy.
Sibley Memorial Hospital
Dr. Mark Markowski is a medical oncologist at the Kimmel Cancer Center at Sibley Memorial Hospital, as well as an Associate Professor in the Department of Oncology at Johns Hopkins University School of Medicine. Dr. Markowski participates in multidisciplinary clinics at Sibley and The Johns Hopkins Hospital, and sees patients in the genitourinary clinics of both hospitals. Dr. Markowski treats numerous types of cancers, with a specialty in prostate and kidney cancers. Dr. Markowski earned his medical degree and Ph.D. in tumor biology at Georgetown University School of Medicine. He completed a residency in internal medicine at Columbia University, followed by a medical oncology fellowship at Johns Hopkins Hospital. Dr. Markowski previously served as a research associate at the Lombardi Comprehensive Cancer Center at Georgetown University. His research interests focus on early phase drug development for prostate cancer, as well a non-castrating therapies for patients with metastatic disease. Dr. Markowski is currently conducting research with funding from a Department of Defense Prostate Cancer Research Program Award and a Challenge Award from the Prostate Cancer Foundation, which focuses on new treatment strategies for prostate cancer patients. Dr. Markowski is rated as a Distinguished provider by MediFind in Hormone Replacement Therapy (HRT). His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Wilms Tumor, Hormone Replacement Therapy (HRT), and Prostatectomy.
Mario Eisenberger is an Oncologist in Baltimore, Maryland. Dr. Eisenberger is rated as a Distinguished provider by MediFind in Hormone Replacement Therapy (HRT). His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Familial Prostate Cancer, Hormone Replacement Therapy (HRT), and Prostatectomy.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- Breast CancerDr. Visvanathan isElite. Learn about Breast Cancer.
- Distinguished
- Ovarian CancerDr. Visvanathan isDistinguished. Learn about Ovarian Cancer.
- Advanced
- Colorectal CancerDr. Visvanathan isAdvanced. Learn about Colorectal Cancer.
- Hormone Replacement Therapy (HRT)Dr. Visvanathan isAdvanced. Learn about Hormone Replacement Therapy (HRT).
- MenopauseDr. Visvanathan isAdvanced. Learn about Menopause.
- Pancreatic CancerDr. Visvanathan isAdvanced. Learn about Pancreatic Cancer.
- Experienced
- Anal CancerDr. Visvanathan isExperienced. Learn about Anal Cancer.
- Cholangiocarcinoma (Bile Duct Cancer)Dr. Visvanathan isExperienced. Learn about Cholangiocarcinoma (Bile Duct Cancer).
- Endometrial CancerDr. Visvanathan isExperienced. Learn about Endometrial Cancer.
- Familial Colorectal CancerDr. Visvanathan isExperienced. Learn about Familial Colorectal Cancer.
- Familial Pancreatic CancerDr. Visvanathan isExperienced. Learn about Familial Pancreatic Cancer.
- HemochromatosisDr. Visvanathan isExperienced. Learn about Hemochromatosis.